Table 2

Clinical and virological characteristics of the 12 HCV/HIV co-infected patients.

Patient

Age

Gender

Genotype

Serum HCV RNA (log10)

Diversity

Complexity


Taq

HF-2

Taq

HF-2


1

49

F

1a

6.37

0.9856

0.9616

4

5

2

40

M

1a

5.96

0.9987

0.9978

2

2

3

36

F

1b

5.53

1.0000

1.0000

1

1

4

38

M

1a

6.75

0.9313

0.9715

8

11

5

42

M

1a

6.94

1.0000

1.0000

1

1

6

40

M

1b

5.55

0.9912

0.9997

5

2

7

41

M

1a

6.39

0.9909

1.0000

6

1

8

45

F

1a

6.25

0.9856

0.9468

4

7

9

47

M

1a

5.68

0.9945

0.9996

2

2

10

41

M

1a

5.92

0.9575

0.9430

10

10

11

61

F

1a

6.83

0.9389

0.9283

7

6

12

51

M

1a

6.99

0.9890

0.9638

2

7

AVG

44.2

6.53

0.9803

0.9760

4.33

5.0


HCV genotypes were determined by INNO-LiPA, while HCV RNA was quantified with the Roche COBAS Monitor assay, and is expressed a log10IU/mL. QS heterogeneity was assessed using the clonal frequency analysis (CFA) technique. Diversity scores represent the average heteroduplex mobility ratios (HMR) for either Taq or HF-2 enzymes. Complexity scores represent the total number of distinct gel shift variants analyzed by CFA. AVG represents average.

Polyak et al. Virology Journal 2005 2:41   doi:10.1186/1743-422X-2-41

Open Data